The TBDA is a novel collaboration of 17 research organizations with the goal of discovering multiple mechanistically distinct TB candidates sufficient to advance a drug regimen to a 1 month POC by 2024.  The TBDA is a groundbreaking partnership between: 8 Pharmaceutical companies (Abbvie, GSK, Lilly, Merck, Eisai, Bayer, AstraZeneca, Sanofi),  5 Major Universities (Cornell, Texas A&M, Colorado State, University of Cape Town, and University of Dundee), 2 Research Institutes (IDRI and Calibr), 1 National Institute (NIAID),1 non profit PDP (TB Alliance). With participation from: Bill and Melinda Gates Foundation. It is managed through the CEO roundtable at the New Venture Fund.